3692 related articles for article (PubMed ID: 7584096)
1. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.
Vile R; Miller N; Chernajovsky Y; Hart I
Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096
[TBL] [Abstract][Full Text] [Related]
2. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.
Vile RG; Nelson JA; Castleden S; Chong H; Hart IR
Cancer Res; 1994 Dec; 54(23):6228-34. PubMed ID: 7954471
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
Siders WM; Halloran PJ; Fenton RG
Cancer Gene Ther; 1998; 5(5):281-91. PubMed ID: 9824047
[TBL] [Abstract][Full Text] [Related]
4. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
Schoensiegel F; Paschen A; Sieger S; Eskerski H; Mier W; Rothfels H; Kleinschmidt J; Schadendorf D; Haberkorn U
Cancer Gene Ther; 2004 Jun; 11(6):408-18. PubMed ID: 15118759
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter.
Ido A; Nakata K; Kato Y; Nakao K; Murata K; Fujita M; Ishii N; Tamaoki T; Shiku H; Nagataki S
Cancer Res; 1995 Jul; 55(14):3105-9. PubMed ID: 7541712
[TBL] [Abstract][Full Text] [Related]
6. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.
Vile RG; Hart IR
Cancer Res; 1993 Sep; 53(17):3860-4. PubMed ID: 8395331
[TBL] [Abstract][Full Text] [Related]
7. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene.
Cao G; Zhang X; He X; Chen Q; Qi Z
In Vivo; 1999; 13(2):181-7. PubMed ID: 10363176
[TBL] [Abstract][Full Text] [Related]
8. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
Emiliusen L; Gough M; Bateman A; Ahmed A; Voellmy R; Chester J; Diaz RM; Harrington K; Vile R
Gene Ther; 2001 Jul; 8(13):987-98. PubMed ID: 11438833
[TBL] [Abstract][Full Text] [Related]
9. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.
Ram Z; Culver KW; Walbridge S; Blaese RM; Oldfield EH
Cancer Res; 1993 Jan; 53(1):83-8. PubMed ID: 8380127
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer.
Anderson LM; Swaminathan S; Zackon I; Tajuddin AK; Thimmapaya B; Weitzman SA
Gene Ther; 1999 May; 6(5):854-64. PubMed ID: 10505111
[TBL] [Abstract][Full Text] [Related]
11. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system.
Parada C; Hernández Losa J; Guinea J; Sánchez-Arévalo V; Fernández Soria V; Alvarez-Vallina L; Sánchez-Prieto R; Ramón y Cajal S
Cancer Gene Ther; 2003 Feb; 10(2):152-60. PubMed ID: 12536204
[TBL] [Abstract][Full Text] [Related]
13. Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and rat glioblastoma cells.
Berenstein M; Adris S; Ledda F; Wolfmann C; Medina J; Bravo A; Mordoh J; Chernajovsky Y; Podhajcer OL
Cancer Gene Ther; 1999; 6(4):358-66. PubMed ID: 10419054
[TBL] [Abstract][Full Text] [Related]
14. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo targeting of gene expression to melanoma cells.
Vile RG; Hart IR
Cancer Res; 1993 Mar; 53(5):962-7. PubMed ID: 8439971
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma.
Okada Y; Okada N; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T
Cancer Gene Ther; 2005 Jul; 12(7):608-16. PubMed ID: 15746944
[TBL] [Abstract][Full Text] [Related]
17. Bystander-mediated regression of osteosarcoma via retroviral transfer of the herpes simplex virus thymidine kinase and human interleukin-2 genes.
Walling HW; Swarthout JT; Culver KW
Cancer Gene Ther; 2000 Feb; 7(2):187-96. PubMed ID: 10770626
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy.
Crittenden M; Gough M; Chester J; Kottke T; Thompson J; Ruchatz A; Clackson T; Cosset FL; Chong H; Diaz RM; Harrington K; Alvarez Vallina L; Vile R
Cancer Res; 2003 Jun; 63(12):3173-80. PubMed ID: 12810645
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
Siders WM; Halloran PJ; Fenton RG
Cancer Res; 1996 Dec; 56(24):5638-46. PubMed ID: 8971169
[TBL] [Abstract][Full Text] [Related]
20. [Retroviral vector-mediated HSVtk gene expression and acquisition of high titer recombinant virus].
Zeng ZJ; Hu WX; Luo SQ; Chen Q
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Dec; 18(4):332-6. PubMed ID: 15650782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
